Adverse reactions occurring in ≥1% of patients undergoing hip or knee replacement surgery in
the 1 Phase II study and the 3 Phase III studies are listed in Table 4.
Table 4:
Table 7:
Bleeding Results in the AMPLIFY-EXT Study
ELIQUIS (apixaban)
2.5 mg bid
N=840
n (%)
Adver 6R&V7F